Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.41 |
| ▸ | CSF1R | P07333 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413746 | 0.86 | KDM4E (0.53) | PTK2KDM4EHSP90AA1HSP90AB1BRAF | |
| SCHEMBL5170655 | 0.82 | CDK2 (0.50) | CDK2GRM5ALDH1A1CSF1R | |
| SCHEMBL6656588 | 0.82 | BRAF (0.62) | CDK2BRAFL3MBTL1 | |
| SCHEMBL6208080 | 0.81 | PIK3CA (0.47) | — | |
| SCHEMBL1431348 | 0.78 | KDM4E (0.47) | PTK2KDM4EHSP90AA1HSP90AB1BRAF | |
| SCHEMBL19736359 | 0.78 | CYP1A2 (0.51) | KDM4EHSP90AA1HSP90AB1BRAFADORA3 | |
| SCHEMBL14518147 | 0.78 | ATR (0.48) | CDK2GRM5CSF1R | |
| SCHEMBL21928148 | 0.77 | KDM4E (0.46) | PTK2KDM4EHSP90AA1HSP90AB1BRAF | |
| SCHEMBL21827821 | 0.77 | KDM4E (0.46) | PTK2KDM4EHSP90AA1HSP90AB1CDK2 | |
| SCHEMBL19706555 | 0.77 | KDM4E (0.46) | PTK2KDM4EHSP90AA1HSP90AB1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970296-B1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2970296-B1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2970296-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| EP-2429993-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2015-01-21 | — | — | EP | disclosed |
| US-8841331-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| WO-2014143610-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014143610-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
| WO-2010130034-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-11-18 | — | — | US | disclosed |
| CN-1745074-A | 5-HT receptor ligands and uses thereof | PFIZER PROD INC (US) | 2006-03-08 | — | — | CN | disclosed |
| US-6894050-B2 | 5-HT receptor ligands and uses thereof | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| EP-1401820-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | Pfizer Products Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | CHIANG PHOEBE (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003000666-A1 | 5-HT RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | PTK2 2650/4885KDM4E 4327/4885HSP90AA1 1136/4885 |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNJ2, KCNA4 | PTK2 4494/4885KDM4E 1004/4885HSP90AA1 3470/4885 |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | PTK2 2650/4885KDM4E 4327/4885HSP90AA1 1136/4885 |
| US-20100292227-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | PTK2 4152/4885KDM4E 1453/4885HSP90AA1 3237/4885 |
| US-20030125334-A1 | 5-HT receptor ligands and uses thereof | HTR1A, HTR2A, HTR5A | PTK2 2285/4885KDM4E 4285/4885HSP90AA1 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.